Lantheus Holdings, Inc. reported second-quarter 2026 results with revenue of $388.18M, up 2.7% from $378.05M a year earlier, net income of $75.03M (down from $78.76M), and diluted EPS of $1.11 compared with $1.12 in the year‑ago quarter — a largely flat per‑share outcome. The quarter reflected grow…
Radiopharmaceutical company Lantheus Holdings NASDAQ:LNTHwill be reporting results this Thursday before the bell. Here’s what investors should know.Lantheus beat analysts’ revenue expectations last quarter, reporting revenues of $377.3 million, up 1.2% year on year. It was a satisfactory quarter fo…
Lantheus approved transaction bonuses allocating $4.0 million to Mary Anne Heino and $500,000 to Daniel M. Niedzwiecki and amended severance agreements for five named executives.Original SEC Filing: Lantheus Holdings, Inc. [ LNTH ] - 8-K - Aug. 03, 2026This is an AI-powered summary. It may contain…
Lantheus announced a definitive merger agreement with Curium under which Curium will acquire the company for $102.50 per share in cash plus a non-transferable contingent value right (CVR) of up to $12.00 per share tied to future sales milestones. The take-private deal is subject to shareholder appr…
Explore more price target data and ratings for Lantheus Holdings, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Lantheus Holdings, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. Thi…
Lantheus Holdings Price Target Maintained With a $115.00/Share by Citizens
Lantheus Holdings Inc NASDAQ:LNTH:
By Puyaan Singh and Sahil PandeyThe U.S. Food and Drug Administration declined to approve Lantheus Holdings’ NASDAQ:LNTH diagnostic imaging kit for types of cancer tumors, citing unresolved issues at a third-party manufacturing facility, the company said on Friday.This marks another setback for La…
The U.S. Food and Drug Administration declined to approve Lantheus Holdings’ NASDAQ:LNTH diagnostic imaging kit for types of cancer tumors, citing unresolved manufacturing-related conditions at a third-party facility, the company said on Friday.
BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) NASDAQ:LNTH, the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food…
